Further more, we had yet another insider buy yesterday. To those of you who think insiders can't & don't trade on insider information think again. They do it all the time without consequence by utilizing the mechanics of 10b5-1 plans. :)
Read the poster and stop worrying about the trading. The results are outstanding! 302 is also a nano therapeutic like 398 so this validates further the platform technology of MACK and increases the likely hood of a successful outcome for 398. MACK will resume its climb as smart money understands the significance of all the recent results. I believe a large deal is in the wings :)
Lol. Yes. They do it all the time though 10b5-1 plans. Educate yourself on the mechanics and you'll understand the significance of these buys.
Possibly. NEA backed. Irrational sell off from misunderstood results. Significant insider buys. Possibly viewed as next OMED type move. MACD crossover indicating buy. ASH presentation in a few days. Big move just starting :)
You are correct! We may even have a great year end. I'm hoping for over $3 with the news heading our way. We shall see. 2014 is our banner year!
They have stated repeatedly that MTD is expected between cohorts 6 and 9 so i would expect such. If MTD is not reached by cohort 9 i think we could see the U of B trial commence before MTD. If there is high efficacy in some tumor types from cohorts 6, 7, or 8 with no DLT this trial could even halt to quickly progress to phase 2 or 2/3 which would still include an arm for dose escalation. MD Anderson is not waiting on this trial. They are conducting their own preclinical work and Beth Israel is waiting on a SPORE grant which will hopefully come early next year.
"The number of Purchase Shares covered by, and the timing of, each Purchase Notice or VWAP Purchase Notice are determined by the Company, at its sole discretion."
Ctix controls when. Aspire does not have advance notice so as to hedge.
" Aspire Capital has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company’s common stock."
9 employees and he is a doctor of pharmacology who developed two blockbuster ant- cancer drugs for Eli Lilly as well as a former Dana Farber researcher under Dr Emil Frei as well as an expert in veterinary oncology and drug development as well as a trained veterinary surgeon. "Nough said"
Lol. I'ld actually be shocked too. I'm hopeful. I think it's Leo's plan. I just don't want financing right now even though all the hubbers do. I want more value first. If we can get p21 data or the Brilacidin trial ready to go first then we get a better deal imo. This of course assumes Leo hasnt partnered. There will be another registration statement coming for the 1.4MM shares used to acquire the PolyMedix assets. But i'm sure the hub will just say that MidCap Financial just wants to be able too sell if the "mood" strikes.
I agree China. Its mind boggling however when over at the hub everyone is wondering where the selling is coming from. They come up with crazy theories when there is an effective registration statement. They can't imagine Aspire would sell. Rather they explain away the registration statement as something that is their just in case they are in the "mood" to sell. Who cares if Aspire sells. I expect them too. It doesnt change my plan. Once the shares are absorbed we trade higher again imo. I think we are close.